Alemtuzumab (Campath-1H) therapy for refractory rejections in pediatric heart transplant recipients

Bibhuti Das; Vivian Dimas; Kristine Guleserian; Chantale Lacelle; Kristin Anton; Lindy Moore; Robert Morrow

doi:10.1111/petr.12844

Alemtuzumab (Campath-1H) therapy for refractory rejections in pediatric heart transplant recipients

Bibhuti Das, Vivian Dimas, Kristine Guleserian, Chantale Lacelle, Kristin Anton, Lindy Moore, Robert Morrow

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

Despite substantial improvements in survival after pediatric heart transplantation, refractory rejection remains a major cause of morbidity and mortality. We have utilized ALE (Campath-1H) in six consecutive patients with refractory rejection. These rejection episodes persisted despite conventional treatment, which included intravenous methylprednisolone, rituximab, immunoglobulin G, and antithymocyte globulin. In our series, after ALE therapy, LV SF increased from 22%±5% to 33%±5% (P=.01). However, in our series, ALE therapy neither led to persistent LV function recovery nor could it prevent subsequent antibody-mediated rejection.

Original language	English (US)
Article number	e12844
Journal	Pediatric Transplantation
Volume	21
Issue number	1
DOIs	https://doi.org/10.1111/petr.12844
State	Published - Feb 1 2017

Keywords

alemtuzumab (Campath-1H)
pediatric heart transplant
refractory acute rejections

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Transplantation

Access to Document

10.1111/petr.12844

Cite this

@article{b2c35b3bff4d48bbaf7d205407669c08,

title = "Alemtuzumab (Campath-1H) therapy for refractory rejections in pediatric heart transplant recipients",

abstract = "Despite substantial improvements in survival after pediatric heart transplantation, refractory rejection remains a major cause of morbidity and mortality. We have utilized ALE (Campath-1H) in six consecutive patients with refractory rejection. These rejection episodes persisted despite conventional treatment, which included intravenous methylprednisolone, rituximab, immunoglobulin G, and antithymocyte globulin. In our series, after ALE therapy, LV SF increased from 22%±5% to 33%±5% (P=.01). However, in our series, ALE therapy neither led to persistent LV function recovery nor could it prevent subsequent antibody-mediated rejection.",

keywords = "alemtuzumab (Campath-1H), pediatric heart transplant, refractory acute rejections",

author = "Bibhuti Das and Vivian Dimas and Kristine Guleserian and Chantale Lacelle and Kristin Anton and Lindy Moore and Robert Morrow",

note = "Publisher Copyright: {\textcopyright} 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd",

year = "2017",

month = feb,

day = "1",

doi = "10.1111/petr.12844",

language = "English (US)",

volume = "21",

journal = "Pediatric Transplantation",

issn = "1397-3142",

publisher = "Wiley-Blackwell",

number = "1",

}

TY - JOUR

T1 - Alemtuzumab (Campath-1H) therapy for refractory rejections in pediatric heart transplant recipients

AU - Das, Bibhuti

AU - Dimas, Vivian

AU - Guleserian, Kristine

AU - Lacelle, Chantale

AU - Anton, Kristin

AU - Moore, Lindy

AU - Morrow, Robert

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Despite substantial improvements in survival after pediatric heart transplantation, refractory rejection remains a major cause of morbidity and mortality. We have utilized ALE (Campath-1H) in six consecutive patients with refractory rejection. These rejection episodes persisted despite conventional treatment, which included intravenous methylprednisolone, rituximab, immunoglobulin G, and antithymocyte globulin. In our series, after ALE therapy, LV SF increased from 22%±5% to 33%±5% (P=.01). However, in our series, ALE therapy neither led to persistent LV function recovery nor could it prevent subsequent antibody-mediated rejection.

AB - Despite substantial improvements in survival after pediatric heart transplantation, refractory rejection remains a major cause of morbidity and mortality. We have utilized ALE (Campath-1H) in six consecutive patients with refractory rejection. These rejection episodes persisted despite conventional treatment, which included intravenous methylprednisolone, rituximab, immunoglobulin G, and antithymocyte globulin. In our series, after ALE therapy, LV SF increased from 22%±5% to 33%±5% (P=.01). However, in our series, ALE therapy neither led to persistent LV function recovery nor could it prevent subsequent antibody-mediated rejection.

KW - alemtuzumab (Campath-1H)

KW - pediatric heart transplant

KW - refractory acute rejections

UR - http://www.scopus.com/inward/record.url?scp=85006022177&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006022177&partnerID=8YFLogxK

U2 - 10.1111/petr.12844

DO - 10.1111/petr.12844

M3 - Article

C2 - 27862703

AN - SCOPUS:85006022177

SN - 1397-3142

VL - 21

JO - Pediatric Transplantation

JF - Pediatric Transplantation

IS - 1

M1 - e12844

ER -

Alemtuzumab (Campath-1H) therapy for refractory rejections in pediatric heart transplant recipients

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this